DBV TECHNOLOGIES SA (DBV.PA)
FR0010417345 - Common Stock
Taking everything into account, DBV scores 3 out of 10 in our fundamental rating. DBV was compared to 79 industry peers in the Biotechnology industry. While DBV seems to be doing ok healthwise, there are quite some concerns on its profitability. DBV is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
DBV had negative earnings in the past year.
In the past year DBV has reported a negative cash flow from operations.
In the past 5 years DBV always reported negative net income.
In the past 5 years DBV always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of DBV (-44.15%) is comparable to the rest of the industry.
The Return On Equity of DBV (-58.44%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.15% | ||
| ROE | -58.44% | ||
| ROIC | N/A |
ROA(3y)-54.89%
ROA(5y)-64.99%
ROE(3y)-75.37%
ROE(5y)-90.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DBV has a better Gross Margin (83.94%) than 83.78% of its industry peers.
In the last couple of years the Gross Margin of DBV has remained more or less at the same level.
DBV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.22%
GM growth 5Y-0.62%
2. Health
2.1 Basic Checks
DBV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DBV has been increased compared to 1 year ago.
The number of shares outstanding for DBV has been increased compared to 5 years ago.
Compared to 1 year ago, DBV has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.07 indicates that DBV is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.07, DBV is doing good in the industry, outperforming 66.22% of the companies in the same industry.
DBV has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of DBV (0.00) is better than 89.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.07 |
ROIC/WACCN/A
WACC7.32%
2.3 Liquidity
DBV has a Current Ratio of 5.86. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.
DBV's Current ratio of 5.86 is amongst the best of the industry. DBV outperforms 85.14% of its industry peers.
DBV has a Quick Ratio of 5.86. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of DBV (5.86) is better than 85.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.86 | ||
| Quick Ratio | 5.86 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.52% over the past year.
DBV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.14%.
The Revenue for DBV have been decreasing by -17.36% on average. This is quite bad
EPS 1Y (TTM)10.52%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q25.67%
Revenue 1Y (TTM)-15.14%
Revenue growth 3Y-30.94%
Revenue growth 5Y-17.36%
Revenue growth Q2Q10.01%
3.2 Future
The Earnings Per Share is expected to grow by 13.10% on average over the next years. This is quite good.
The Revenue is expected to grow by 79.35% on average over the next years. This is a very strong growth
EPS Next Y31.48%
EPS Next 2Y14.89%
EPS Next 3Y17.72%
EPS Next 5Y13.1%
Revenue Next Year-13.45%
Revenue Next 2Y33.44%
Revenue Next 3Y-19.41%
Revenue Next 5Y79.35%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
DBV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DBV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as DBV's earnings are expected to grow with 17.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.89%
EPS Next 3Y17.72%
5. Dividend
5.1 Amount
DBV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DBV TECHNOLOGIES SA
EPA:DBV (4/19/2024, 7:00:00 PM)
1.24
-0.01 (-0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap238.60M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.15% | ||
| ROE | -58.44% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.86 | ||
| Quick Ratio | 5.86 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)10.52%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y31.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-15.14%
Revenue growth 3Y-30.94%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y